These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
321 related articles for article (PubMed ID: 21479319)
41. Nanotoxicology: the molecular science point of view. Pumera M Chem Asian J; 2011 Feb; 6(2):340-8. PubMed ID: 20725923 [TBL] [Abstract][Full Text] [Related]
43. Comparative study of predictive computational models for nanoparticle-induced cytotoxicity. Sayes C; Ivanov I Risk Anal; 2010 Nov; 30(11):1723-34. PubMed ID: 20561263 [TBL] [Abstract][Full Text] [Related]
44. Safety assessment of personal care products/cosmetics and their ingredients. Nohynek GJ; Antignac E; Re T; Toutain H Toxicol Appl Pharmacol; 2010 Mar; 243(2):239-59. PubMed ID: 20005888 [TBL] [Abstract][Full Text] [Related]
45. Grey goo on the skin? Nanotechnology, cosmetic and sunscreen safety. Nohynek GJ; Lademann J; Ribaud C; Roberts MS Crit Rev Toxicol; 2007 Mar; 37(3):251-77. PubMed ID: 17453934 [TBL] [Abstract][Full Text] [Related]
46. Manufacture and use of nanomaterials: current status in the UK and global trends. Aitken RJ; Chaudhry MQ; Boxall AB; Hull M Occup Med (Lond); 2006 Aug; 56(5):300-6. PubMed ID: 16868127 [TBL] [Abstract][Full Text] [Related]
47. Toxicological assessment of divalent ion-modified ZnO nanomaterials through artificial intelligence and in vivo study. Chandrasekaran K; Kakani V; Kokkarachedu V; Abdulrahman Syedahamed HH; Palani S; Arumugam S; Shanmugam A; Kim S; Kim K Aquat Toxicol; 2024 Feb; 267():106826. PubMed ID: 38219502 [TBL] [Abstract][Full Text] [Related]
48. Risk management strategy to increase the safety of workers in the nanomaterials industry. Ling MP; Lin WC; Liu CC; Huang YS; Chueh MJ; Shih TS J Hazard Mater; 2012 Aug; 229-230():83-93. PubMed ID: 22727485 [TBL] [Abstract][Full Text] [Related]
49. Nanotechnology: the next big thing, or much ado about nothing? Maynard AD Ann Occup Hyg; 2007 Jan; 51(1):1-12. PubMed ID: 17041243 [TBL] [Abstract][Full Text] [Related]
50. An in vitro assessment of panel of engineered nanomaterials using a human renal cell line: cytotoxicity, pro-inflammatory response, oxidative stress and genotoxicity. Kermanizadeh A; Vranic S; Boland S; Moreau K; Baeza-Squiban A; Gaiser BK; Andrzejczuk LA; Stone V BMC Nephrol; 2013 Apr; 14():96. PubMed ID: 23617532 [TBL] [Abstract][Full Text] [Related]
51. Rationale of genotoxicity testing of nanomaterials: regulatory requirements and appropriateness of available OECD test guidelines. Warheit DB; Donner EM Nanotoxicology; 2010 Dec; 4():409-13. PubMed ID: 20925448 [TBL] [Abstract][Full Text] [Related]
52. Toxicological aspects of long-term treatment of keratinocytes with ZnO and TiO2 nanoparticles. Kocbek P; Teskac K; Kreft ME; Kristl J Small; 2010 Sep; 6(17):1908-17. PubMed ID: 20677183 [TBL] [Abstract][Full Text] [Related]
54. [Organizing the supervision over the turnover of nanomaterials presenting a potential hazard to human health]. Onishchenko GG Gig Sanit; 2011; (2):4-9. PubMed ID: 21604392 [TBL] [Abstract][Full Text] [Related]
55. Nanotechnology and human health: risks and benefits. Cattaneo AG; Gornati R; Sabbioni E; Chiriva-Internati M; Cobos E; Jenkins MR; Bernardini G J Appl Toxicol; 2010 Nov; 30(8):730-44. PubMed ID: 21117037 [TBL] [Abstract][Full Text] [Related]
56. [Safety assessment of nanomaterials for development of nano-cosmetics]. Yoshida T; Yoshioka Y; Tsutsumi Y Yakugaku Zasshi; 2012; 132(11):1231-6. PubMed ID: 23123712 [TBL] [Abstract][Full Text] [Related]
57. Research strategies for safety evaluation of nanomaterials, part VII: evaluating consumer exposure to nanoscale materials. Thomas T; Thomas K; Sadrieh N; Savage N; Adair P; Bronaugh R Toxicol Sci; 2006 May; 91(1):14-9. PubMed ID: 16476686 [TBL] [Abstract][Full Text] [Related]